Acute renoprotective effects of dapagliflozin monotherapy on albuminuria and metabolic derangements in newly diagnosed type 2 diabetes mellitus: a quasi-experimental study | Synapse
March 3, 2026Open Access
Acute renoprotective effects of dapagliflozin monotherapy on albuminuria and metabolic derangements in newly diagnosed type 2 diabetes mellitus: a quasi-experimental study
Key Points
Dapagliflozin significantly reduces albuminuria levels in newly diagnosed type 2 diabetes patients, indicating renal protective effects.
The study reports a notable improvement in metabolic parameters associated with dapagliflozin treatment, with clear benefits observed.
Quasi-experimental analysis shows substantial changes in renal function markers, marking the intervention's effectiveness in managing diabetes-related complications.
These findings suggest the need for further research into dapagliflozin's long-term effects on renal health in diverse diabetic populations.